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Mutacin II is a lantibiotic that is produced by group II Streptococcus mutans. It inhibits the growth of other
streptococci as well as many other gram-positive microorganisms by a hitherto unknown mechanism. Mutacin
II possesses bactericidal activity against susceptible cells. It transiently depolarizes the transmembrane
electrical potential (Dc) and the transmembrane pH gradient (DpH) and partially inhibits amino acid
transport. However, it rapidly depletes the intracellular ATP pool in glucose-energized cells and prevents the
generation of ATP. It is concluded that mutacin II does not belong to the group of pore-forming lantibiotics
(type A) or to the type B lantibiotics, which inhibit phospholipases or interfere with peptidoglycan biosynthesis.
Mutacin II acts by inhibiting essential enzyme functions at the level of metabolic energy generation, an activity
that has not yet been classified for lantibiotics.
Mutans streptococci as well as many other microorganisms
which inhabit the oral cavity produce antimicrobial substances
of a proteinaceous nature (13). These are referred to as bac-
teriocins (27) or bacteriocin-like inhibitory substances (32).
The term ‘‘mutacin’’ has been proposed for antimicrobial pep-
tides originating from Streptococcus mutans (8). These antimi-
crobial peptides can play significant roles in primary coloniza-
tion and give a competitive advantage to producer strains
occupying critical ecological niches in dental plaque. There-
fore, bacteriocins have several potential biotechnological ap-
plications and have been explored for their ability to provide
protection against bacteria causing dental diseases (10, 11).
Recently, mutacin II was isolated from S. mutans T8 and
partially characterized (21). It is a small (3,245 Da) peptide,
and on the basis of chemical modification techniques and ion
spray mass spectroscopy, it contains one b-methyllanthionine
and two lanthionines in addition to a didehydro amino acid
(22). These data suggest that mutacin II belongs to the lantibi-
otic group of bacteriocins (12). Mutacin II is stable and bio-
logically active over a wide range of pH values and tempera-
tures (21).
In this study the mode of action of mutacin II has been
analyzed. The results suggest that mutacin II acts in a bacte-
ricidal manner and that it interferes with the capacity of cells to
generate metabolic energy. Its biological activity appears to be
directed at the inhibition of enzyme functions.
MATERIALS AND METHODS
Bacterial strains and media. S. mutans NTCC 10449, Streptococcus sanguis
Ny101 (21), and Lactococcus lactis subsp. lactis IL1403 (4) were used as mutacin
II-susceptible strains. Cells were grown in brain heart infusion broth or agar
(Difco Laboratories, Detroit, Mich.) at 308C (for L. lactis) or at 378C (for the
Streptococcus spp. and Escherichia coli) without aeration. Purified nisin was
purchased from NBS Biologicals (North Mymms, Hatfield, Herts, United King-
dom) or obtained from Aplin & Barrett and stored at 2208C in acetic acid
solution (pH 3.0) at 10 mg/ml.
Purification of mutacin II and determination of its biological activity.Mutacin
II was purified as described by Nova´k et al. (21). Bacteriocin activity in prepared
samples was determined by the agar spot tests (9). In short, 10 ml of a solution
containing bacteriocin was spotted on an agar plate in serial twofold dilutions in
demineralized water containing 0.5% (vol/vol) Tween 20. After the liquid had
been completely absorbed by the agar, a top agar layer seeded with 0.1% of an
overnight culture of susceptible S. sanguis Ny101 was poured over the plates. The
plates were incubated for 16 h at 378C and examined for zones of growth
inhibition. The highest dilution which produced a distinct zone of inhibition after
this incubation period was defined as 1 arbitrary unit (AU). One arbitrary unit
corresponded to about 0.035 mg of purified mutacin II and 0.025 mg of purified
nisin.
Effect of mutacin II on growth of susceptible cells. Overnight cultures were
diluted to approximately 6 3 106 cells per ml and tested for their susceptibility
to different concentrations of mutacin II. Briefly, aliquots of 0.1-ml samples were
taken at 30-min intervals to determine the viable count by plating onto brain
heart infusion agar. In order to detect lytic activity, optical density (OD) was
determined either at 595 nm (Bio-kinetics reader EL 312e; Bio-Tek Instruments)
or at 630 nm (DIAS microplate reader; Dynatech Laboratories, Guernsey,
United Kingdom), depending on the instrument used in the experiment.
Measurement of the transmembrane electrical potential. The transmembrane
electrical potential (Dc) in cells was determined with an electrode specific for the
lipophilic cation tetraphenylphosphonium (31) as described previously (3).
Measurement of intracellular pH. The intracellular pH was determined by the
use of the fluorescent pH probe 29,79-bis-(2-carboxyethyl)-5[and 6]-carboxyfluo-
rescein (BCECF; Molecular Probes, Inc., Eugene, Oreg.), which was trapped in
L. lactis IL1403 cells by an acid shock (17). Cells suspended in 50 mM potassium
phosphate (pH 6.0) were energized with 0.5% (wt/vol) glucose at 308C, and the
BCECF fluorescence was monitored with a Perkin-Elmer LS50B spectrofluo-
rimeter with computer-controlled data acquisition and storage using excitation
and emission wavelengths of 502 and 525 nm, respectively. The excitation and
emission slit widths were 5.0 and 15.0 nm, respectively. Data were corrected for
ATP-driven efflux of the fluorescent probe (18), and the fluorescent signal was
calibrated by measuring the fluorescence at different pH values in the presence
of 1 mM nigericin to equilibrate protons across the membrane (17). DpH was
calculated from the difference between intracellular pH and medium pH.
Transport assays. The uptake of the amino acids [1-14C]2-a-aminoisobutyric
acid (AIB) (8.5 mM; 59 mCi/mmol) and L-[U-14C]glutamate (1.75 mM; 285
mCi/mmol) was analyzed as described previously (3).
Determination of intracellular ATP concentration. Cells were harvested at
late exponential growth phase (OD at 600 nm [OD600] of 1.2), washed once with
100 mM potassium phosphate (pH 6.5), and concentrated to an OD600 of about
3.0 (23). The cell suspension was energized with 0.5% (wt/vol) glucose, and
aliquots of the suspension were taken at specific time points. Samples were mixed
with half a volume of 14% (wt/vol) perchloric acid–9 mM Na2EDTA. The
supernatant was neutralized with half a volume of 1 M KOH–1 M KHCO3. The
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neutralized extract was diluted 40-fold into 40 mM Tris-SO4, and just before the
measurement 2 mM EDTA (pH 7.75) and 10 mMMgSO4 were added. ATP was
measured by the firefly luciferase assay as described previously (23).
RESULTS
Mutacin II is a bactericidal lantibiotic. To investigate the
mode of action of the lantibiotic mutacin II against the sus-
ceptible cells, an overnight culture of S. sanguis Ny101 was
diluted in fresh brain heart infusion broth with and without 10
AU of mutacin II per ml and the viable count and optical
density changes were determined as a function of time. After 1
h of incubation in the presence of mutacin II, 96% of the cells
lost their ability to form colonies (Fig. 1A). After 3 h of treat-
ment only 0.003% of the cells survived, but further incubation
(i.e., 18 h) resulted in increases in both OD and colony forming
ability, suggesting the appearance of resistant cells. Cell lysis,
as detected by a change in OD of the cells, was not observed
during the time of experiment. Stationary-phase (18 h) Ny101
cells were at least twofold more susceptible to mutacin II than
exponentially growing cells (6 h) (data not shown). These data
suggest that mutacin II acts in a bactericidal manner.
After prolonged (18 h) growth in the presence of the bac-
teriocin, a subpopulation of Ny101 cells was able to grow.
Rapid growth of these cells (Ny101R) was observed when they
were incubated in fresh growth medium, both in the absence
(Fig. 1B, solid boxes) and in the presence (open boxes) of 30
AU of mutacin II per ml. This apparent resistance was lost
when the cells were grown for 24 h in the absence of the
bacteriocin (data not shown).
The surfactant cocolactobionamide enhances the bacteri-
cidal activity of mutacin II. Some lantibiotics act at the level of
the cytoplasmic membrane of susceptible cells (7), and their
activity may be enhanced in the presence of surfactants that
are thought to increase access to the phospholipids (5).
Growth of susceptible S. mutans NTCC 10449 cells was mon-
itored following treatment with a partially inhibiting concen-
tration of mutacin II, the surfactant cocolactobionamide (1),
and a combination of both. The data shown in Fig. 1C dem-
onstrate that the surfactant has a synergistic antibacterial effect
when added in combination with mutacin II, whereas little
inhibition of growth is observed with surfactant alone.
Mutacin II transiently and partially depolarizes the trans-
membrane electrical potential and pH gradient. To study
whether mutacin II was capable of permeabilizing the cytoplas-
mic membrane of susceptible cells, its effect on the transmem-
brane electrical potential (Dc) was determined by monitoring
the distribution of the lipophilic cation tetraphenylphospho-
nium in energized cells. The Dc of susceptible S. sanguis Ny101
cells that were either treated (Fig. 2B) or not treated (data not
shown) with nigericin was transiently depolarized by 30 AU of
mutacin II per ml. However, the dissipation was not complete,
and it was only temporary. Under the same set of conditions,
FIG. 1. Mutacin II activity against susceptible lactic acid bacteria. (A) Mutacin II possesses bactericidal activity against S. sanguisNy101 cells. Symbols:h, log OD595
of control cells (no additions); n, log CFU of control cells (no additions) per ml; E, log OD595 of cells treated with 10 AU of mutacin II per ml; F, per ml, log CFU
of cells treated with 10 AU of mutacin II per ml. (B) Spontaneous occurrence of mutacin II-resistant S. sanguis Ny101 cells. Partially resistant Ny101 cells (Ny101R)
were obtained by growing NY101 cells in the presence of 10 AU of mutacin per ml for 18 h. Ny101R (squares) or Ny101 (circles) cells were inoculated onto fresh
medium with (h and E) and without (n and F) 30 AU of mutacin II per ml, and the log OD595 was monitored. (C) Synergistic antibacterial effect of mutacin II and
the surfactant cocolactobionamide on S. mutans NTCC 10449. Symbols: h, control cells (no additions); n, 0.005% (wt/vol) cocolactobionamide; F, 8.25 AU of mutacin
II per ml; E, 0.005% (wt/vol) cocolactobionamide and 8.25 AU of mutacin II per ml. Growth was monitored by measuring the OD630.
FIG. 2. Effect of mutacin II on the Dc of glucose-energized cells of S. sanguis
Ny101. (A) Control; (B) cells treated with 30 AU of mutacin II per ml; (C) cells
pretreated with 30 AU of mutacin II per ml. Arrows indicate the following
additions: c, cells; g, 0.4% (wt/vol) glucose; n, 1.0 mM nigericin; v, 1.0 mM
valinomycin; and m, 30 AU of mutacin II per ml. The traces show the response
of the tetraphenylphosphonium ion (TPP1)-selective electrode as a qualitative
measure of the Dc.
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30 AU of nisin per ml completely collapsed the Dc (data not
shown) (7). The Dc recovered shortly after the cells were
treated with mutacin II. In contrast, the potassium ionophore
valinomycin elicited a complete dissipation of the Dc (Fig. 2A).
When susceptible cells were preincubated with mutacin II be-
fore the energy source glucose was added, no significant effect
of repeated additions of mutacin II on the Dc was observed
(Fig. 2C). In no instance was a complete depolarization of the
Dc by mutacin II observed. Similar results were obtained with
susceptible L. lactis IL1403 cells, whereas the Dc of resistant S.
sanguis Ny101 cells (Ny101R) was not affected by mutacin II
(data not shown). These results suggest that mutacin II only
temporarily affects the ion permeability of the cytoplasmic
membrane of susceptible cells and that it does not form stable
pores.
To study the effect of mutacin II on the transmembrane pH
gradient (DpH) of susceptible cells, L. lactis IL1403 cells were
loaded with the fluorescent pH indicator BCECF to monitor
the intracellular pH. When cells were energized with glucose,
a rapid increase in the intracellular pH was observed (Fig. 3).
Dissipation of the Dc by valinomycin (1 mM) resulted in a
further increase in the intracellular pH. Addition of nigericin
(1 mM), a K1/H1 ionophore (Fig. 3, trace 1), or the lantibiotic
nisin (30 AU/ml) (trace 4) rapidly reversed the intracellular pH
to a level equal to that of the medium pH. Four repeated
additions of 50 AU of mutacin II per ml each (trace 2) or one
single addition of 200 AU of mutacin II per ml (data not
shown) caused a small but reproducible dissipation of the pH
gradient. These results indicate that mutacin II has only a
minor effect on the proton permeability of the cytoplasmic
membrane.
Mutacin II inhibits the uptake of amino acids. The influence
of mutacin II on the proton motive force-dependent uptake of
AIB (6, 15), a nonmetabolizable analog of alanine (33), by
energized susceptible (Ny101) (Fig. 4A) and partially resistant
(Ny101R) cells (Fig. 4B) was studied. AIB is rapidly accumu-
lated by both Ny101 and Ny101R cells. Addition of valinomy-
cin and nigericin (1 mM each) (Fig. 4A, solid boxes; added at
the arrow) caused a slow but complete release of the accumu-
lated AIB. On the other hand, addition of mutacin II (100
AU/ml; solid circles) resulted in only a partial release of accu-
mulated AIB to the level observed when the cells were prein-
cubated with mutacin prior to the addition of AIB (open cir-
cles). Mutacin II hardly affected the uptake of AIB by Ny101R
cells (Fig. 4B). The partial inhibition of AIB uptake in suscep-
tible cells is consistent with the observation that mutacin II
elicits a partial collapse of proton motive force.
Glutamate uptake by lactic acid bacteria is a phosphate-
bond-linked (ATP-driven), unidirectional process that is not
dependent on the proton motive force (24, 25). Cells of Ny101
efficiently retained the accumulated glutamate upon the addi-
tion of the ionophores valinomycin and nigericin (1 mM each)
(Fig. 5, diamonds; added at arrow A), but complete release was
effected by the pore forming lantibiotic nisin (solid boxes). In
contrast, mutacin II (100 AU/ml) (solid circles) again caused
only a partial release of the accumulated glutamate to the level
that was observed when cells were preincubated with mutacin
II prior to the addition of glutamate (open circles). Prior ad-
dition of valinomycin and nigericin had little effect on the
mutacin II-induced release of glutamate, indicating that the
proton motive force is not required for functioning of mutacin
II. Mutacin II did not elicit glutamate release from Ny101R
cells (data not shown). These results demonstrate that mutacin
II transiently permeabilizes the membrane and that this per-
meabilization is accompanied by a short burst in which solutes
like glutamate are released.
Mutacin II depletes the intracellular ATP pool in glucose-
energized cells. To investigate whether mutacin II affects the
FIG. 3. Effect of mutacin II on the DpH of glucose-energized cells of L. lactis
IL1403. Cells were loaded with the fluorescent pH indicator BCECF to record
intracellular pH changes as described in Materials and Methods. Glucose (0.5%
[wt/vol]) and valinomycin (1.0 mM) were added at the respective arrows. At the
numbered arrows the following sequential additions were made: trace 1, nigeri-
cin (1.0 mM) at time point 1; trace 2, 50 AU of mutacin II per ml at time points
2, 3, and 4 and 1.0 mM nigericin at time point 5; trace 3, no additions; and trace
4, 50 AU of nisin per ml at time point 6. The fluorescence level was converted
into intracellular pH values for the cells after calibration and correction for
BCECF efflux.
FIG. 4. Effect of mutacin II on AIB uptake by glucose-energized cells of S.
sanguis Ny101 (A) and Ny101R (B). Symbols: h, control cells (no additions); n,
1 mM valinomycin and 1 mM nigericin added at the time indicated by the arrow;
F, 100 AU of mutacin II per ml added at the time indicated by the arrow; E, cells
pretreated with 100 AU of mutacin II per ml for 1 min prior to the addition of
AIB.
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level of intracellular ATP, susceptible L. lactis IL1403 cells
were energized with glucose and the impact of 100 AU of
mutacin II per ml on the ATP level was measured. Addition of
mutacin II to the cells resulted in a nearly complete depletion
of the intracellular ATP pool (Fig. 6). In cells preincubated
with mutacin II, virtually no ATP was generated upon the
addition of glucose. These data demonstrate that mutacin II
depletes the entire intracellular ATP pool and thereby dramat-
ically affects the energetic status of susceptible cells.
DISCUSSION
Mutacin II is a bacteriocin produced by some strains of oral
streptococci (32). In this study the effect of mutacin II on
susceptible cells was analyzed. Mutacin II is bactericidal, but
the mechanism of its activity is not yet clear. A transient and
only partial dissipation of the Dc and DpH occurred upon the
addition of mutacin II. This effect was accompanied by a par-
tial release of AIB and glutamate. Further additions of muta-
cin II did not result in a greater effect. In vivo labelling exper-
iments using intracellular DNA with the specific membrane-
impermeable fluorescent label propidium iodide demonstrated
that mutacin II does not cause the disruption of the cells or a
subset thereof (2). Therefore, it appears that the initial inter-
action of mutacin with the cells is responsible for the transient
and incomplete permeabilization of the membrane for ions
and small solutes. The principal biological activity of mutacin
II appears not to rely on pore formation, in contrast to the
activity of type A lantibiotics such as nisin (7, 28–30). A dra-
matic effect of mutacin II on the cellular ATP levels was ob-
served. Addition of mutacin II caused a complete depletion of
the intracellular ATP pool. Therefore, it seems likely that the
partial depolarization of the proton motive force is the indirect
result of the permeation of these molecules across the cyto-
plasmic membrane to gain access to the cytosol. There, it may
interact with the primary target, for instance, with enzymes
involved in the generation of metabolic energy at the substrate
level. The mechanism by which mutacin II depletes the intra-
cellular ATP pool is so far obscure. Mutacin may either inhibit
the enzymes involved in ATP generation or activate ATPases
to induce futile cycling and a depletion of available ATP. In
this respect, barely any effect of mutacin II on the rate of
glycolysis (as measured by the rate of acid production) of
lactococcal cells (2) or on the uptake of the nonmetabolizable
carbohydrate analog methyl-b-D-thiogalactopyranoside (19)
was observed. On the other hand, mutacin II also does not
appear to belong to the group of type B lantibiotics, which
contains, e.g., cinnamycin, duramycin, mersacidin, and actagar-
dine (28), globular polypeptides that act as enzyme inhibitors.
The primary target of these type B lantibiotics is peptidoglycan
synthesis or inhibition of phospholipases. The primary target of
mutacin II seems not to be related to either of these phenom-
enona; rather, mutacin II seems to be directed at the inhibition
of metabolic energy generation.
When cells are grown in the presence of mutacin II, a spon-
taneous development of cells that appear to be resistant to the
lantibiotic occurs. Intriguingly, this phenomenon is not a stable
attribute, since it requires that the cells remain exposed to the
lantibiotic. The mechanism of this apparent resistance is not
known, but the spontaneous occurrence suggests that there is
FIG. 5. Effect of mutacin II on L-glutamate uptake by glucose-energized cells
of S. sanguis Ny101. Symbols: h, control cells (no additions); F, 100 AU of
mutacin II per ml added at the time indicated by arrow B; }, 1 mM valinomycin
and 1 mM nigericin added at the time indicated by arrow A and 100 AU of
mutacin II per ml added at the time indicated by arrow B;E, cells pretreated with
100 AU of mutacin II per ml (1 min) prior to the addition of glutamate; n, 100
AU of nisin per ml added at the time indicated by arrow B.
FIG. 6. Effect of mutacin II on the intracellular ATP level in glucose-ener-
gized cells of L. lactis IL1403. Symbols: n, control cells (no additions); h, 100
AU of mutacin II per ml added at the time point indicated by the arrow; F, cells
pretreated with 100 AU of mutacin II per ml for 1 min prior to the addition of
0.5% (wt/vol) glucose.
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heterotypy among the bacteria as far as their susceptibility to
mutacin II is concerned. This may limit the use of mutacin II
in dental applications. A phenotypically similar resistance has
recently been described for pediocin AcH (20). In the natural
environment, however, the bacterium-killing effect of mutacin
II may occur in combination with extracellular acid production.
S. mutans and other lactic acid bacteria convert fermentable
carbohydrates primarily to lactic acid (for a review see refer-
ence 34), and this helps these organisms to maintain their
niche. For instance, lactic acid produced by food-grade micro-
organisms acts as a preservative (26), while lactic acid produc-
tion by oral streptococci and lactobacilli has been implicated in
the dissolution of tooth enamel and thus in the pathogenesis of
dental caries (14). Therefore, combinational effects of the bac-
teriocins and extracellular acid production may suppress
growth of competing microbial floras in the respective ecosys-
tems.
In summary, mutacin II is bactericidal and inhibits cell met-
abolic processes in an unknown, voltage-independent manner,
thereby causing cell death without visible lysis.
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